Jan 29, 2025, 07:37
Bishal Gyawali: Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X:
“Ever wondered why the results of 3 immunotherapy trials in urothelial cancers are different? Is it truly because the 3 drugs are different?
In this smart study led by Tomer Meirson, we show that these differences can all be explained by differential censoring alone! ”
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Authors: Tomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, Avital Bareket-Samish, Gal Markel, Victoria Neiman, Nathan Cherny, Daniel A. Goldstein, Bishal Gyawali, Ian Tannock, Eli Rosenbaum.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 29, 2025, 22:27
Jan 29, 2025, 22:26
Jan 29, 2025, 22:26